Identification of DNA methylation-independent epigenetic events underlying clear cell renal cell carcinoma

Cancer Research

Volumn 76, Issue 7, 2016, Pages 1954-1964

  Becket, Elinne ^a   Chopra, Sameer ^a   Duymich, Christopher E ^a   Lin, Justin J ^b   You, Jueng Soo ^c   Pandiyan, Kurinji ^a   Nichols, Peter W ^d   Siegmund, Kimberly D ^a   Charlet, Jessica ^a   Weisenberger, Daniel J ^d   Jones, Peter A ^a,e   Liang, Gangning ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Konkuk University School of Medicine   (South Korea)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VON HIPPEL LINDAU PROTEIN;

ARTICLE; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU TUMOR SUPPRESSOR GENE; GENETICS; PATHOLOGY; PROCEDURES;

CARCINOMA, RENAL CELL; DNA METHYLATION; EPIGENOMICS; GENE EXPRESSION; HUMANS;

EID: 84963746001     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-2622     Document Type: Article

References (42)

1. Gupta KM, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008;34:193-205.
2. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009;373:1119-32.
3. Bhatt JR, Finelli A. Landmarks in the diagnosis and treatment of renal cell carcinoma. Nat Rev Urol 2014;11:517-25.
4. Bignell GR, Greenman CD, Davies H, Butler AP, Edkins S, Andrews JM, et al. Signatures of mutation and selection in the cancer genome. Nature 2010;463:893-8.
5. Dancey JE, Bedard PL, Onetto N, Hudson TJ. The genetic basis for cancer treatment decisions. Cell 2012;148:409-20.
6. Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499:43-9.
7. Morris MR, Maher ER. Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics. Genome Med 2010;2:59.
8. Jones PA. Functions of DNA Methylation: islands, start sites, gene bodies, and beyond. Carcinogenesis 2012;31:27-36.
9. Morgan MA, Shilatifard A. Chromatin signatures of cancer. Genes Dev 2015;29:238-49.
10. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013;339:1546-58.
11. De Carvalho DD, Sharma S, You JS, Su SF, Taberlay PC, Kelly TK, et al. DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell 2012;21:655-67.
12. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol 2010;28:1069-78.
13. Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet 2012;13:679-92.
14. Wee S, Dhanak D, Li H, Armstrong SA, Copeland RA, Sims R, et al. Targeting epigenetic regulators for cancer therapy. Ann N Y Acad Sci 2014;1309:30-6.
15. You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 2012;22:9-20.
16. Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell 2013;153:38-55.
17. Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011;11:726-34.
18. Bell O, Tiwari VK, Thoma NH, Schubeler D. Determinants and dynamics of genome accessibility. Nat Rev Genet 2011;12:554-64.
19. Pandiyan K, You JS, Yang X, Dai C, Zhou XJ, Baylin SB, et al. Functional DNA demethylation is accompanied by chromatin accessibility. Nucleic Acids Res 2013;41:3973-85.
20. Campan MW, Weisenberger DJ, Trinh B, Laird PW. MethyLight. Methods Mol Biol 2009;507:325-37.
21. Yang X, Han H, De Carvalho DD, Lay FD, Jones PA, Liang G. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell 2014;26:577-90.
22. Lay FD, Liu Y, Kelly TK, Witt H, Farnham PJ, Jones PA, et al. The role of DNA methylation in directing the functional organization of the cancer epigenome. Genome Res 2015;25:467-77.
23. Chodavarapu RK, Feng S, Bernatavichute YV, Chen PY, Stroud H, Yu Y, et al. Relationship between nucleosome positioning and DNA methylation. Nature 2010;466:388-92.
24. Lorch YL, La Pointe JW, Kornberg RD. Nucleosomes inhibit the initiation of transcription but allow chain elongation with the displacement of histones. Cell 1987;49:203-10.
25. Ay A, Arnosti DN. Nucleosome positioning: an essential component of the enhancer regulatory code? Curr Biol 2010;20:R404-6.
26. Taberlay PC, Kelly TK, Liu CC, You JS, De Carvalho DD, Miranda TB, et al. Polycomb-repressed genes have permissive enhancers that initiate reprogramming. Cell 2011;147:1283-94.
27. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, et al. Epigenetic stem cell signature in cancer. Nat Genet 2007;39:157-8.
28. Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008;40:741-50.
29. Gal-Yam EN, Egger G, Iniguez L, Holster H, Einarsson S, Zhang X, et al. Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc Natl Acad Sci U S A 2008;105:12979-84.
30. Kelly TK, Liu Y, Lay FD, Liang G, Berman BP, Jones PA. Genome-wide mapping of nucleosome positioning and DNA methylation within individual DNA molecules. Genome Res 2012;22:2497-506.
31. Pekowska A, Benoukraf T, Zacarias-Cabeza J, Belhocine M, Koch F, Holota H, et al. H3K4 tri-methylation provides an epigenetic signature of active enhancers. EMBO J 2011;30:4198-210.
32. Rada-Iglesias A, Bajpai R, Swigut T, Brugmann SA, Flynn RA, Wysocka J. A unique chromatin signature uncovers early developmental enhancers in humans. Nature 2011;470:279-83.
33. Komashko VM, Farnham PJ. 5-Azacytidine treatment reorganizes genomic histone modification patterns. Epigenetics 2010;5:229-40.
34. Wolff EM, Chihara Y, Pan F, Weisenberger DJ, Siegmund KD, Sugano K, et al. Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res 2010;70:8169-78.
35. Network. CGAR. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499:43-9.
36. Duns G, Van Den Berg E, Van Duivenbode I, Osinga J, Hollema H, Hofstra RM, et al. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res 2010;70:4287-91.
37. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010;463:360-3.
38. Weisenberger DJ. Characterizing DNA methylation alterations from The Cancer Genome Atlas. J Clin Invest 2014;124:17-23.
39. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007;39:232-6.
40. Han H, Cortez CC, Yang X, Nichols PW, Jones PA, Liang G. DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter. Hum Mol Genet 2011;20:4299-310.
41. Cassano A, Bagalá C, Battelli C, Schinzari G, Quirino M, Ratto C, et al. Expression of vascular endothelial growth factor, mitogen-activated protein kinase and p53 in human colorectal cancer. Anticancer Res 2002;22:2179-84.
42. Allison SJ, Knight JRP, Granchi C, Rani R, Minutolo F, Milner J, et al. Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD (H)-dependent and (ii) p53-independent pathways. Oncogenesis 2014;3:1-11.